Itron, Inc.
ITRIItron, Inc. is cheap for a reason. The P/E sits at the 24th percentile of its own range, and the quarters are still getting worse.
The sharpest disagreement: annual EPS moved +25.5% against a −21.3% price move — the market has not yet caught up with the delivery.
The price is topping out (1 weeks in) while the P/E sits at the 24th percentile of its own 3-year range. Underneath, the last four quarters read deteriorating — profit −28.6% year on year, and 120% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Itron, Inc. trades at $107, losing momentum at the top and 1 weeks into that stage. That is +12.7% against its own 200-day average. It sits at 49% of a 52-week range of $79 to $136. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 1 straight week.
Today the stock is losing momentum at the top — week 1 of stage 3. At $107 it trades +12.7% versus its 200-day average and sits at 49% of its 52-week range ($79–$136).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +149% while the S&P 500 moved +248% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 1 straight week — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 24th percentile of its own range.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Itron, Inc. trades at 17.8× P/E, near the bottom of its own range — cheaper only 24% of the time. Its long-run median P/E is 22.7×, measured across 3.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 17.8× is near the bottom of its own range — cheaper only 24% of the time, against a long-run median of 22.7× measured over 3.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
One caveat before moving on: margins are the best this company has ever printed — cheap against its own history on record margins is not the same thing as cheap. If profitability mean-reverts, today's multiple is higher than it looks.
Why the multiple sits where it does: over the past year annual EPS moved +25.5% against a −21.3% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 3y, of the +11.8%/yr price move, ~+94.7%/yr came from earnings growth and ~−82.9 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Itron, Inc. reads as mixed on its fundamental arc. Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +350.0% at its peak to +11.5% but is still expanding, ROCE holding at 10.5%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −2.9% | +9.6% | — | — |
| Profit | +25.0% | — | — | — |
| EPS | +25.5% | — | — | — |
| Stock price | −21.3% | +11.8% | +1.6% | +9.6% |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
42.5/100 — rank 17 of 19 in Scientific & Technical Instruments · 82% evidence confidence
Itron, Inc. scores 42.5 out of 100 against the 19 companies it is compared with in Scientific & Technical Instruments, ranking 17. Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
The four contributions add to the total exactly: 9.6 + 9 + 14.6 + 9.3 = 42.5. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Itron, Inc. reported $0.6 B of revenue in the Mar 26 quarter, −3.3% year on year. Over 4 years it has compounded at 4.6% a year. The last full year, FY25, came in at $2.4 B. The last four reported quarters add to $2.3 B.
Itron, Inc. reported $0.6 B of revenue in the Mar 26 quarter, −3.3% year on year. Over 4 years it has compounded at 4.6% a year. The last full year, FY25, came in at $2.4 B. The last four reported quarters add to $2.3 B.
FY25 revenue came in at $2.4 B (−2.9% on the year), capping 4 years at 4.6% compound. The latest quarter (Mar 26) printed $0.6 B, −3.3% year on year.
Pace check: the last four quarters averaged −4.1% growth against the decade's 4.6% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −4.1% over the last 4 quarters against +1.5%/yr over the last 8 — rolling over; TTM profit +11.5% vs +34.6%/yr — rolling over.
→ Revenue slipped — did margins hold as it scaled? Next: 11.9% this quarter (−1.2 pp YoY).
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Itron, Inc.'s operating margin is 11.9% in the Mar 26 quarter, −1.2 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged −4.0% to 13.1%. The current quarter sits inside that band.
Itron, Inc.'s operating margin is 11.9% in the Mar 26 quarter, −1.2 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged −4.0% to 13.1%. The current quarter sits inside that band.
The latest quarter's operating margin is 11.9%, −1.2 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −4.0%–13.1%, and FY25's 13.1% is the top of that band — a record year.
🚨 Why the margin moved: operating margin went −1.2 pp year on year while gross margin went +4.6 pp — the loss came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
→ Margins slipped — did that reach the bottom line? Next: profit −28.6% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Itron, Inc. earned $0.1 B of net profit in the Mar 26 quarter, −28.6% year on year. Full-year FY25 profit was $0.3 B. That is 8.5% of the quarter's revenue. The same quarter a year earlier earned $0.1 B.
Itron, Inc. earned $0.1 B of net profit in the Mar 26 quarter, −28.6% year on year. Full-year FY25 profit was $0.3 B. That is 8.5% of the quarter's revenue. The same quarter a year earlier earned $0.1 B.
Mar 26 profit was $0.1 B, −28.6% year on year. On the full year, FY25 printed $0.3 B (+25.0%).
🚨 Why profit moved: revenue contributed −3.3% and the margin −1.2 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +16.4% vs revenue −4.1%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.
→ Profit rose — but did the cash follow? Next: 120% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 120% of Itron, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.4 B of operating cash against $0.3 B of profit. After $0.0 B of capital spending, $0.4 B was left as free cash.
FY25: operating cash of $0.4 B against reported profit of $0.3 B, leaving free cash of $0.4 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 120% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
→ So follow the cash to where it goes. Next: $0.0 B of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Itron, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROE is 17% and the ROIC − WACC spread is +1.4 pp.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Itron, Inc. earns a ROE of 17% in FY25. That is up from a trough of −7% in FY21. Return on invested capital clears the cost of that capital by +1.4 percentage points, so growth here adds value rather than only size. The wiring behind it is 12.7% net margin on 0.64× asset turns.
FY25 ROE is 17%, recovered from a FY21 trough of −7% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 12.7% net margin × 0.64× asset turns × 2.14× balance-sheet leverage ≈ 17.4% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 10.3% − 8.9% = a +1.4 pp spread. The 8.9% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.98.
Dividend
Itron, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Itron, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
→ No payout to follow. The cash question becomes what the business does with what it earns instead.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Itron, Inc. carries total debt of $1.6 B against shareholder equity of $1.6 B as of Mar 26, a debt-to-equity of 0.98. On the annual view that ratio went from 0.45 in FY21 to 0.73 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of $1.6 B against shareholder equity of $1.6 B — a debt-to-equity of 0.98. On the annual view, debt-to-equity went from 0.45 (FY21) to 0.73 (FY25). Read the returns on this page with that leverage in mind.
→ Who owns this, and are they adding or leaving? Next: short interest is 14.1% of the float.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
14.1% of Itron, Inc.'s tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 9.5 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 14.1% of the float is sold short, and at typical trading volumes it would take about 9.5 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Itron, Inc.: the Z-score reads 2.48. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits in the grey band between the two. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 2.48 sits in the grey band — neither clearly safe nor clearly distressed.
The safety line in one sentence: the Z-score reads 2.48.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Itron, Inc. this page | 17.8× | $5B | Mixed | |||
| Keysight Technologies, Inc. | 50.0× | $52B | Turning around | |||
| Garmin Ltd. | 28.3× | $49B | Consistent | |||
| Coherent Corp. | 101.6× | $48B | No read | |||
| Teledyne Technologies Incorporated | 31.4× | $30B | Turning around | |||
| Fortive Corporation | 37.7× | $19B | Deteriorating | |||
| MKS Inc. | 59.7× | $19B | Mixed | |||
| Trimble Inc. | 30.5× | $14B | Deteriorating | |||
| Cognex Corporation | 71.0× | $10B | Improving | |||
| ESCO Technologies Inc. | 26.6× | $8B | Mixed | |||
| Sensata Technologies Holding plc | 144.3× | $7B | Deteriorating | |||
| Novanta Inc. | 100.2× | $5B | Deteriorating | |||
| Vontier Corporation | 11.6× | $5B | Mixed | |||
| Badger Meter, Inc. | 31.5× | $4B | Mixed | |||
| Vishay Precision Group, Inc. | 206.1× | $1B | Turning around | |||
| Ituran Location and Control Ltd. | 18.1× | $1B | Consistent | |||
| Mesa Laboratories, Inc. | 83.6× | $1B | No read | |||
| USBC, Inc. | — | $0B | No read | |||
| MicroVision, Inc. | — | $0B | No read |
Frequently asked questions
What is Itron, Inc.'s stock price today?
Itron, Inc. trades at $107, −21.3% over the past year. The company is valued at $5.0 B. The stock sits at 49% of its 52-week range of $79–$136, +12.7% versus its 200-day average. On the tape, the price is topping out, 1 weeks in. — as of 29 July 2026.
What were Itron, Inc.'s latest quarterly results?
Itron, Inc. reported revenue of $0.6 B and net profit of $0.1 B for the Mar 26 quarter. Revenue fell 3.3% and profit fell 28.6% year on year. Earnings per share were $1.18. The operating margin was 11.9%, 1.2 pp lower than a year earlier. — as of 29 July 2026.
What is Itron, Inc.'s revenue?
Itron, Inc. reported revenue of $0.6 B in the Mar 26 quarter, −3.3% year on year. For the full FY25 fiscal year, revenue was $2.4 B (−2.9%). Over the last 4 years revenue compounded at 4.6% a year. — as of 29 July 2026.
What is Itron, Inc.'s profit?
Itron, Inc. earned $0.1 B of net profit in the Mar 26 quarter, −28.6% year on year. Full-year FY25 profit was $0.3 B. The operating margin ran 11.9% in the latest quarter. — as of 29 July 2026.
What is Itron, Inc.'s market cap?
Itron, Inc.'s market capitalisation is $5.0 B at a stock price of $107. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 29 July 2026.
What is Itron, Inc.'s P/E ratio?
Itron, Inc. trades at a P/E of 17.8×, at the 24th percentile of its own 3-year range, against a long-run median of 22.7×. This is a comparison with the stock's own history, not a value call — as of 29 July 2026.
Does Itron, Inc. pay a dividend?
No — Itron, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 29 July 2026.
Is Itron, Inc. overvalued?
On its own history, Itron, Inc. looks cheap against its own history: its P/E of 17.8× has been cheaper only 24% of the time in 3 years (long-run median 22.7×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 29 July 2026.
Is Itron, Inc. growing?
Not right now — Itron, Inc.'s latest numbers are shrinking: latest-quarter revenue −3.3% year on year, profit −28.6%, and the margin −1.2 pp at 11.9%. The earnings engine currently reads: deteriorating — as of 29 July 2026.
How is Itron, Inc. performing?
Itron, Inc. is topping out, 1 weeks in. Its latest quarter's revenue fell 3.3% and profit fell 28.6% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 29 July 2026.
What stage is Itron, Inc. in?
Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +350.0% at its peak to +11.5% but is still expanding, ROCE holding at 10.5%. The read comes from the last 12 quarters of growth (revenue growth −4.1% latest, profit growth +11.5% latest, eps growth +14.4% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 29 July 2026.
Is Itron, Inc. in an uptrend?
It is stalling — the price is topping out (week 1 of stage 3), trading +12.7% versus its 200-day average and at 49% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 29 July 2026.
Is Itron, Inc. beating the market?
On recent form, yes — Itron, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 1 straight week, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +149% against the S&P 500's +248% — behind the index over the full window. — as of 29 July 2026.
Will Itron, Inc.'s stock price go up?
This page publishes no price forecast for Itron, Inc. What it measures instead: the stock price is $107, the price is topping out 1 weeks in. Its P/E of 17.8× sits at the 24th percentile of its own 3-year range. Direction is not something this site claims to know. — as of 29 July 2026.
Is the market betting against Itron, Inc.?
Yes — short interest is 14.1% of Itron, Inc.'s tradable float, about 9.5 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 29 July 2026.
Does Itron, Inc. have too much debt?
It is moderate — Itron, Inc.'s debt-to-equity is 0.98. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 29 July 2026.
What is Itron, Inc.'s capex?
Itron, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 29 July 2026.
What is Itron, Inc.'s cash flow?
Itron, Inc. generated $0.4 B of operating cash flow in FY25 and $0.4 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.3 B, so operating cash ran ahead of profit. — as of 29 July 2026.
Is Itron, Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 120% of Itron, Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $0.4 B against reported profit of $0.3 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 29 July 2026.
How financially safe is Itron, Inc.?
On the balance sheet, the Z-score reads 2.48 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is in the grey band — neither clearly safe nor clearly distressed. — as of 29 July 2026.
Where is Itron, Inc. in its business cycle?
Itron, Inc.'s FY25 operating margin was 13.1%, against a 5-year band of −4.0%–13.1%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 11.9%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 29 July 2026.
What could break the Itron, Inc. story?
The sharpest disagreement: annual EPS moved +25.5% against a −21.3% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 29 July 2026.
Is Itron, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Itron, Inc. is cheap for a reason. The P/E sits at the 24th percentile of its own range, and the quarters are still getting worse. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 29 July 2026.